1296 related articles for article (PubMed ID: 35304222)
1. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
2. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
3. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
[TBL] [Abstract][Full Text] [Related]
4. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
[TBL] [Abstract][Full Text] [Related]
5. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
6. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ; Bhatt DL; Kinninger A; Lakshmanan S; Muhlestein JB; Le VT; May HT; Shaikh K; Shekar C; Roy SK; Tayek J; Nelson JR
Eur Heart J; 2020 Oct; 41(40):3925-3932. PubMed ID: 32860032
[TBL] [Abstract][Full Text] [Related]
7. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE; Jacobson TA; Maki KC
J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
[TBL] [Abstract][Full Text] [Related]
8. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
9. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
10. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Nelson JR; True WS; Le V; Mason RP
Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
[TBL] [Abstract][Full Text] [Related]
11. A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.
Huston J; Schaffner H; Cox A; Sperry A; Mcgee S; Lor P; Langley L; Skrable B; Ashchi M; Bisharat M; Gore A; Jones T; Sutton D; Sheikh-Ali M; Berner J; Goldfaden R
Am J Cardiovasc Drugs; 2023 Jul; 23(4):393-406. PubMed ID: 37188993
[TBL] [Abstract][Full Text] [Related]
12. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.
Gaba P; Bhatt DL; Mason RP; Miller M; Verma S; Steg PG; Boden WE;
J Clin Lipidol; 2022; 16(4):389-402. PubMed ID: 35773147
[TBL] [Abstract][Full Text] [Related]
13. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
14. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
15. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
Boden WE; Bhatt DL; Toth PP; Ray KK; Chapman MJ; Lüscher TF
Eur Heart J; 2020 Jun; 41(24):2304-2312. PubMed ID: 31872245
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
[TBL] [Abstract][Full Text] [Related]
17. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
Boden WE; Baum S; Toth PP; Fazio S; Bhatt DL
Future Cardiol; 2021 Jan; 17(1):155-174. PubMed ID: 32959713
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki KC; Dicklin MR
Curr Opin Cardiol; 2020 Jul; 35(4):417-422. PubMed ID: 32412960
[TBL] [Abstract][Full Text] [Related]
19. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Miller M; Tardif JC; Ketchum SB; Doyle RT; Murphy SA; Soni PN; Braeckman RA; Juliano RA; Ballantyne CM;
Clin Cardiol; 2017 Mar; 40(3):138-148. PubMed ID: 28294373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
